FibroGen Announces Reverse Stock Split Effective June 16

FibroGen ( (FGEN) ) has provided an update.

On June 10, 2025, FibroGen, Inc. announced a 1-for-25 reverse stock split of its common stock, effective June 16, 2025. This move aims to increase the stock’s market price to meet Nasdaq’s listing requirements, reducing the number of outstanding shares significantly. The reverse split was approved by stockholders on June 4, 2025, and will affect all outstanding shares and equity incentive plans. Trading on a split-adjusted basis will begin on June 17, 2025.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

Spark’s Take on FGEN Stock

According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.

FibroGen’s overall stock score is driven by significant financial challenges, including declining revenues and persistent losses, which weigh heavily on its financial health. The technical analysis provides mixed signals, and the valuation remains unattractive due to negative earnings. Although the earnings call presented strategic advancements, the underlying financial issues are substantial concerns that dominate the overall assessment.

To see Spark’s full report on FGEN stock, click here.

More about FibroGen

FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia. Its key product, Roxadustat, is approved in several countries for treating anemia in chronic kidney disease patients. The company is also developing FG-3246, an antibody-drug conjugate, for metastatic castration-resistant prostate cancer.

Average Trading Volume: 917,817

Technical Sentiment Signal: Strong Sell

Current Market Cap: $31.24M

Find detailed analytics on FGEN stock on TipRanks’ Stock Analysis page.